Geraldine A Hamilton,
President/Chief Scientific Officer,
Emulate Inc
Dr. Hamilton's career spans academic research, large Pharma, and biotech start-ups, with over 10 years’ experience in the pharmaceutical industry. In all three arenas, Dr. Hamilton's work has focused on the development of new human-relevant cell-based models and their application to drug discovery. This pursuit brought Dr. Hamilton to Harvard's Wyss Institute, where as a Lead Senior Staff Scientist she directed the extensive Organs-on-Chips project. This project was successfully spun-out from the Wyss Institute to form Emulate, Inc., where Dr. Hamilton now serves as President and Chief Scientific Officer. At Emulate, Dr. Hamilton continues her work to further develop Organs-on-Chips technology as well as to drive and facilitate its adoption in commercial use. Prior to joining the Wyss Institute and Emulate, Dr. Hamilton was one of the founding scientists of the biotech start-up CellzDirect, where she was the VP of Scientific Operations and Director of Cell Products. CellzDirect successfully translated and commercialized technology from academic research to supply the pharmaceutical industry with hepatic cell products and services for safety assessment and drug-metabolism studies. Hamilton received her Ph.D. in cell biology/toxicology from the University of Hertfordshire (England) in conjunction with GlaxoSmithKline, followed by a post-doctoral research fellowship at the University of North Carolina. She has led in vitro toxicology and drug metabolism teams in GlaxoSmithKline and AstraZeneca. Her current research interests and scientific experience include: bioinspired engineering, toxicology and drug metabolism, liver cell biology, mechanisms regulating gene expression and differentiation, regulation of nuclear receptors and transcriptional activation in hepatocytes by xenobiotics, human cell isolation and cryopreservation techniques.
|
|
|